Kamada's $50M Plasma Deal: A Masterclass in Strategic Confidence

REHOVOT, Israel and HOBOKEN, N.J. – July 20, 2026 – In a move that speaks volumes about strategic foresight and execution, Kamada Ltd. today announced a three-year, $50 million agreement to supply plasma to an undisclosed leading biopharmaceutical company. While the identity of the partner remains confidential, the intent behind the deal is crystal clear: Kamada is cementing its transformation from a specialized product manufacturer into a vertically integrated powerhouse in the global plasma-derived therapies market.

The agreement leverages Kamada's newly operational, FDA-approved plasma collection centers in Texas to supply normal source plasma, with initial sales slated to begin in the fourth quarter of this year. For a company that has methodically built its capabilities from the ground up, this deal is not merely a new revenue stream; it is the capstone on a multi-year investment and a powerful signal of confidence to the market.

"We are very pleased to announce this supply agreement which validates the investment we made in our U.S.-based state-of-the-art plasma collection centers,” said Amir London, Chief Executive Officer of Kamada, in the company's official statement. “This important agreement supports both our vertical-integration strategy, as well as our multi-year revenue growth objectives."

Validating a Vertical Vision

In the high-stakes world of biopharmaceuticals, controlling one's own supply chain is the ultimate power play. For manufacturers of plasma-derived therapies, securing a stable, high-quality source of the primary raw material—human plasma—is a critical determinant of success. Kamada's deal is a textbook example of this principle in action. It represents the successful execution of the third pillar in its four-part growth strategy: ramping up plasma collection to serve both its internal needs and the broader market.

The company's vertical integration strategy is a calculated move to de-risk its operations. By owning the collection process, Kamada gains greater control over supply continuity, quality, and cost, insulating itself from the volatility of the third-party plasma market. This $50 million contract is the first major external validation of that strategy. It proves that the company can not only collect plasma for its own proprietary products but also produce it at a scale and quality sufficient to attract a major industry player as a customer. This effectively turns a cost center and internal resource into a significant profit center.

This strategic pivot is backed by FIMI Opportunity Funds, Israel's leading private equity firm and Kamada's controlling shareholder. FIMI's 38% stake provides the financial stability and long-term perspective necessary to undertake such capital-intensive projects as building out a network of U.S.-based plasma centers. The move signals a deep-seated belief that the future of the plasma industry belongs to those who control the resource from donation to final product.

The Texas Plasma Pipeline

The foundation of this landmark agreement lies nearly 6,000 miles from Kamada's Israeli headquarters, in the state of Texas. Over the past few years, the company has quietly and methodically built a trio of FDA-approved plasma collection centers that form the backbone of its new operational capacity. The Houston center became operational in 2024 and received its FDA license in 2025, while the San Antonio facility followed, starting operations in 2025 and gaining its own FDA approval in the first half of 2026. A third center in Beaumont specializes in collecting hyper-immune plasma, the critical ingredient for Kamada's own specialty products like KEDRAB® and WINRHO SDF®.

This new agreement will primarily draw upon the normal source plasma collected at the Houston and San Antonio locations. Each of these state-of-the-art facilities is designed for a planned capacity of approximately 50,000 liters per year, meaning that at full ramp-up, they represent a significant new source of plasma for the global market. The $50 million deal secures a buyer for a substantial portion of this output for the next three years, creating a predictable revenue stream that underwrites the initial investment.

The successful and timely ramp-up of these centers, culminating in their FDA approvals, cannot be overstated. It demonstrates a high level of operational excellence and an ability to navigate the complex U.S. regulatory landscape. As CEO Amir London noted, "We are pleased with the pace of our collection ramp-up activities, and we thank our teams in Texas for their excellent work." This quiet execution is the bedrock upon which such significant commercial deals are built.

Reading the Plasma Market Signals

Beyond the direct financial impact, Kamada's agreement sends several important signals to the broader biopharmaceutical industry. The global market for plasma-derived therapeutics is dominated by giants like CSL Behring, Takeda, and Grifols, and is characterized by a persistent and growing demand. The fact that an unnamed "leading" company has chosen to source a significant volume of plasma from Kamada, a relatively new entrant to large-scale collection, is telling. It suggests that the demand for high-quality plasma may be outstripping the collection capacity of even the largest players, forcing them to secure supply from reliable new partners.

The confidentiality surrounding the partner's identity is itself a strategic signal, highlighting the intensely competitive nature of plasma sourcing. Securing a stable supply is a distinct competitive advantage, and the partner company likely wishes to keep its sourcing strategy under wraps. For Kamada, this anonymity does little to diminish the deal's significance; it reinforces its arrival as a serious supplier in the plasma value chain.

From a financial perspective, the deal adds approximately $16.7 million in annual revenue, contributing to the double-digit growth analysts have been projecting for Kamada in 2026. Notably, management has confirmed that expected sales from this agreement in the fourth quarter are already included in the company's current annual guidance. This is the mark of a confident leadership team that doesn't rely on surprising the market but on executing a well-communicated, long-term plan. This confidence is echoed by financial analysts, with firms like H.C. Wainwright and Benchmark recently affirming "Buy" ratings and setting ambitious price targets of $13.00 and $15.00, respectively.

This deal does not exist in a vacuum. It follows other recent successes, including a multi-million dollar extension of a supply tender with Canadian Blood Services for four of Kamada's specialty products. Taken together, these developments paint a picture of a company firing on all cylinders—growing its core specialty product business, expanding its distribution portfolio, and now successfully monetizing its strategic investment in vertical integration. It's a multi-pronged approach that is building a more resilient, profitable, and influential Kamada.